{"id":"NCT01342081","sponsor":"Santen Pharmaceutical Co., Ltd.","briefTitle":"DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%","officialTitle":"A Double-masked Study of DE-111 Ophthalmic Solution Versus Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension -Phase 3, Confirmatory Study-","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05","primaryCompletion":"2012-09","completion":null,"firstPosted":"2011-04-26","resultsPosted":"2015-05-14","lastUpdate":"2015-06-15"},"enrollment":489,"design":{"allocation":null,"model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Open Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"DE-111 ophthalmic solution","otherNames":[]},{"type":"DRUG","name":"Tafluprost ophthalmic solution 0.0015%","otherNames":[]},{"type":"DRUG","name":"Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"},{"label":"3","type":"ACTIVE_COMPARATOR"}],"summary":"DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used concomitantly, in IOP(intraocular pressure) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a multicenter, randomized, double-masked, parallel-group comparison study. Safety will be compared and evaluated as well.","primaryOutcome":{"measure":"Change From Baseline in Mean Diurnal IOP(Intraocular Pressure) at End of Study","timeFrame":"Week 0(Baseline) and Week 4(End of Study)","effectByArm":[{"arm":"DE-111","deltaMin":-2.6,"sd":1.8},{"arm":"Tafluprost","deltaMin":-0.9,"sd":1.7},{"arm":"Tafluprost Plus Timolol","deltaMin":-2.2,"sd":1.8}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":161},"commonTop":[]}}